{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.18","upperLimit":"2.60","value":"0.89"}]}]}],"denomUnitsSelected":"Total Patient-years at Risk","denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"338"}],"units":"Total Patient-years at Risk"}],"description":"Malignancies were clinical findings of cancer and excluded non-melanoma skin cancer. Multiple events reported in the same participant were counted multiple times in the calculation of incidence. Incidence rate is defined as events per 100 patient years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with GPA (Wegener's granulomatosis) or MPA who received rituximab as per investigator's discretion were followed for a maximum of 4.32 years.","id":"OG000","title":"Rituximab"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received any active dose of rituximab.","reportingStatus":"POSTED","timeFrame":"From first dose until participant withdrawal or the date of last participant, last visit (up to 4.32 years)","title":"Incidence Rate of Malignancy, Excluding Non-melanoma Skin Cancer","type":"SECONDARY","typeUnitsAnalyzed":"Total Patient-years at Risk","unitOfMeasure":"events per 100 patient year"}